Galectin Therapeutics reported $71.74M in Debt for its fiscal quarter ending in December of 2023.





Debt Change Date
AbbVie USD 72.86B 5.36B Mar/2026
Bristol-Myers Squibb USD 46.43B 711M Mar/2026
Galectin Therapeutics USD 71.74M 10.6M Dec/2023
Gilead Sciences USD 22.17B 2.76B Mar/2026
Immunic USD 0 0 Jun/2024
Incyte USD 38.27M 1.16M Jun/2026
Merck USD 49.12B 222M Mar/2026